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Abstract: Metabolic reprogramming, which is characteristic of cancer cells that rapidly adapt to the
hypoxic microenvironment and is crucial for tumor growth and metastasis, is recognized as one of
the major mechanisms underlying therapeutic resistance. Mitochondria, which are directly involved
in metabolic reprogramming, are used to design novel mitochondria-targeted anticancer agents.
Despite being targeted by melatonin, the functional role of mitochondria in melatonin’s oncostatic
activity remains unclear. In this study, we aim to investigate the role of melatonin in mitochondrial
metabolism and its functional consequences in head and neck cancer. We analyzed the effects of
melatonin on head and neck squamous cell carcinoma (HNSCC) cell lines (Cal-27 and SCC-9), which
were treated with 100, 500, and 1500 µM of melatonin for 1, 3, and 5 days, and found a connection
between a change of metabolism following melatonin treatment and its effects on mitochondria.
Our results demonstrate that melatonin induces a shift to an aerobic mitochondrial metabolism that
is associated with changes in mitochondrial morphology, function, fusion, and fission in HNSCC.
We found that melatonin increases oxidative phosphorylation (OXPHOS) and inhibits glycolysis
in HNSCC, resulting in increased ROS production, apoptosis, and mitophagy, and decreased cell
proliferation. Our findings highlight new molecular pathways involved in melatonin’s oncostatic
activity, suggesting that it could act as an adjuvant agent in a potential therapy for cancer patients.
We also found that high doses of melatonin, such as those used in this study for its cytotoxic impact
on HNSCC cells, might lead to additional effects through melatonin receptors.
Keywords: melatonin; head and neck cancer cells; mitochondria; OXPHOS; glycolysis; mitophagy;
apoptosis; free radicals
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1. Introduction
Head and neck squamous cell carcinoma (HNSCC), one of the most aggressive tumors,
accounts for 80–90% of all malignant neoplasms in the oral cavity [1]. Despite advances
in the treatments available, there is a low overall 5-year survival due to high recurrence.
New anticancer therapeutic strategies are required to prevent or reverse the development
of chemoresistance, which is a major obstacle to HNSCC management. Recent studies
highlighted the important role played by tumoral metabolism in HNSCC [2–4]. Increasing
evidence indicates that cancer could be considered a mitochondrial metabolic disease
in which metabolic reprogramming plays a key role with regard to tumorigenesis and
metastasis [5]. The energy needs of tumor cells are met through aerobic glycolysis, thus,
limiting the transformation of glucose into acetyl-coenzyme A (acetyl-CoA). This in turn
generates lactate and lowers the pH in the local environment, which play a key role in
tumor cell migration and metastasis [6]. However, the maintenance of glycolysis when
oxygen is present requires metabolic reprogramming which involves both epigenetic and
genetic changes (the so-called Warburg effect) [7]. These changes, which are associated with
a wide spectrum of metabolic adjustments, increases cell proliferation and self-renewal,
as well as poor cell differentiation. Given the differences between cancer and normal
cell metabolism, it is vital to precisely elucidate the molecular mechanisms involved in
mitochondrial metabolism reprogramming and to provide effective drug repositioning
therapeutic strategies to target metabolic reprogramming.
Many essential mitochondrial functions play a much more important role in cancer
metabolism than previously thought [8]. Cancer cell mitochondria are novel therapeutic
targets given their structural and functional differences from their normal cell counterparts.
Increased production of reactive oxygen species (ROS) also generates mutations involving
malignant transformation and cancer progression, thus making these organelles promising
targets of anticancer therapy. However, ATP production in normal cells might be disrupted
by the targeting of mitochondrial ATP production, while mitochondrial ROS-mediated sig-
naling in immune cells might be disrupted when mitochondrial redox status is targeted [9].
To resolve this problem, cancer cell mitochondria need to be targeted without damaging
normal cell mitochondria [5].
Melatonin (N-acetyl-5-methoxytryptamine) is a potent anti-inflammatory and antioxi-
dant molecule. Moreover, melatonin attracts attention as an oncostatic agent. However,
the precise mechanism of the action involved in the oncostatic anti-neoplastic impact of
melatonin is not fully elucidated. The involvement of mitochondria in the anti-proliferative
effect of melatonin on neoplastic cells is of particular relevance for the development of inno-
vative cancer treatments [10–14]. Indeed, we found that melatonin amplifies the cytotoxic
effects of chemotherapy and radiotherapy in HNSCC, which are associated with changes
in mitochondrial respiratory capacity and ROS balance in these cells [10,11]. Changes in
mitochondrial respiration are well-known to contribute to metabolic remodeling, although
the mechanism of action involved in melatonin-driven tumoral death remains unclear.
Moreover, previous studies showed that melatonin not only enhances the oncostatic effects
of radio- or chemotherapy on tumor cells, but also protects normal cells against the adverse
effects of these treatments [10,12,14,15].
In this study, we tested the hypothesis that the effects of melatonin on cancer cells can
be explained by bioenergetic stress, resulting from the inability of tumor cells to switch on
glycolysis, in order to produce ATP, following the inhibition of oxidative phosphorylation
(OXPHOS). To investigate this hypothesis, we targeted tumor cell metabolism in HNSCC
following melatonin treatment. We confirmed the cytotoxic effect of melatonin on HNSCC
and its involvement in a change of metabolism in these cancer cells and also determined
the precise mechanism of action involved. We aimed to understand the mechanisms that
lead to tumor progression in HNSCC and to provide evidence for melatonin treatment
strategies for HNSCC that is aimed at the targeting metabolism.
Antioxidants 2021, 10, 603 3 of 20
2. Materials and Methods
2.1. Cell Culture and Treatment
Head and neck squamous carcinoma cells Cal-27 (ATCC: CRL-2095) and SCC-9 (ATCC:
CRL-1629) were obtained from the Cell Bank of the Scientific Instrumentation Centre of the
University of Granada. Cal-27 cells were grown, as previously described [10], in Dulbecco’s
Modified Eagles Medium-GlutaMAX (DMEM, high glucose, GlutaMAX™ Supplement,
Fisher Scientific, 41965039, Madrid, Spain) with 10% fetal bovine serum (FBS) (16000044;
Fisher Scientific Madrid, Spain), 1 mM sodium pyruvate, and 2% antibiotic/antimycotic so-
lution (15240062, Fisher Scientific, Madrid, Spain). SCC-9 cells were cultured in DMEM-F12
Nutrient Mixture Ham medium (11320033; Fisher Scientific, Madrid, Spain) supplemented
with 10% FBS, 2% antibiotic/antimycotic solution, 2 mM L-glutamine (25030081; Fisher
Scientific, Madrid, Spain), 0.5 mM sodium pyruvate, and 0.4 µg/mL hydrocortisone. Both
cell lines were maintained in a humidified 37 ◦C incubator with 5% CO2. Cal-27 and
SCC-9 cells were negative for mycoplasma, tested using a PCR detection kit, following the
manufacturer’s instructions (25235; LiliF Diagnostics, Burlington, MA, USA).
Melatonin (33457-24; Fagron Ibérica S.A.U., Terrasa, Spain) stock solution was pre-
pared in 15% propylene glycol (PG; 24414.296; VWR, Radnor, PA, USA) in phosphate
buffer solution (PBS) (14190-094, Life Technologies) and filter-sterilized through a 0.2 µm
pore filter (Sartorius Biotech GmbH, Gottingen, Germany). Cells were grown to 60–70%
confluence and serum starved for 24 h. They were then treated with different melatonin
concentrations (0, 100, 500, and 1500 µM) for 24, 72, and 120 h (1, 3, and 5 days). Vehicle
was added to the control group.
2.2. Metabolomic Analysis
The TCA cycle metabolites, citric acid, succinyl-CoA, acetyl-CoA, NADH, and lactic
acid, were quantitatively determined by ultraperformance liquid chromatography, in
combination with triple quadrupole mass spectrometry (UPLC-MS/MS), at the Center
for Omic Sciences (Rovira i Virgili University, Tarragona, Spain). Since metabolic changes
are observed in a short period of time, cells were treated with melatonin only for 6 h
for metabolomic analysis. After harvesting the cells, the metabolites were extracted by a
liquid–liquid extraction with hexane. Samples were analyzed in a 1290 Infinity LC Series
chromatograph coupled with a 6495 iFunnel Triple Quad MS/MS (Agilent Technologies,
Santa Clara, USA) equipped with an AQUITY UPLC HSS T3 1.8 µm, 2.1 × 100 mm column
(Waters, Milford, USA). The mobile phase used was 20 mM NH4AC and 0.2% acetic acid
as solvent A and acetonitrile (ACN) as solvent B. The column flow was 0.5 mL/under the
following mobile phase gradient conditions—0–1 min 0% B isocratic, 5 min 50% B, 6–9 min
100% B isocratic, and 10 min 0% B with a post run of 3 min. The volume of injection was
5 µL. Ionization was performed using a source of electrospray (ESI), with a temperature
and flow of Drying Gas (N2) of 290 ◦C and 18 L/min respectively, a nebulization gas (N2)
pressure of 20 psi and a sheath gas (N2) temperature and flow of 350 ◦C and 10 L/min. The
fragment or voltage was 380 V, capillary voltage was 3500 V in the positive and 3000 in the
negative and the nozzle voltage was 750 V in the positive and 1500 V in the negative mode.
Detection was performed in the QqQ detector through acquisition of Multiple Reaction
Monitoring (MRM). Quantification of samples was performed through interpolation of the
obtained area in the standard curve with the matrix match method.
2.3. Pyruvate Measurement
Intracellular pyruvate concentration was measured using a colorimetric assay kit
(EPYR-100, BioAssay Systems, Hayward, CA, USA) in a microplate reader spectrophotome-
ter (Power Wave X-1; Bio-Tek Instruments, Inc., Winooski, VT, USA) at 570 nm, according
to the manufacturer’s instructions Data were normalized by the protein content measured
by Bradford assay.
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2.4. Mitochondrial Respiration
The oxygen consumption rate (OCR) was determined using the Seahorse Extracellular
Flux XF-24 analyzer (Seahorse Bioscience, N.Billerica, MA, USA). Cells were seeded in XF
24-well cell culture microplates (Seahorse Bioscience) at a density of 8 × 104 cells/well and
incubated overnight at 37 ◦C with 5% CO2. Prior to performing the assay, the medium
was changed to Base Medium (102353-100, Seahorse Bioscience, N. Billerica, MA, USA)
containing 10 mM glucose, 5 mM pyruvate, and 2 mM glutamine, and the cells were
equilibrated for 1 h at 37 ◦C without CO2.
The OCR was measured as previously described [16], both at the basal level and
in response to modulators of maximal mitochondrial electron transport system (ETS)
capacity. A total of 1 µM oligomycin and 1 µM trifluorocarbonylcyanide phenylhydrazone
(FCCP) (0.5 µM in two injections) were injected, followed by 1 µM rotenone/antimycin A.
Inhibition of ATP synthase by oligomycin was used to determine the proportion of OCR
used for ATP production under basal conditions. Maximal uncoupled respiration was
assessed after the addition of FCCP, and the residual nonmitochondrial OCR was measured
using rotenone/antimycin A. The average of four readings per cell line was recorded, and
it was normalized by the number of cells. Cells were counted in a hemocytometer, and
viability was determined by trypan blue staining.
2.5. Measurement of Redox Status
ROS production was measured using 100 µM of 2′ 7′ dichlorofluorescin diacetate
(DCFH-DA) probe (Sigma-Aldrich, Madrid, Spain), according to the protocol described
by Shen et al. [10]. DCFH-DA was transformed into the fluorescent DCF inside the cell.
Fluorescence was then measured with the microplate fluorescence reader FLx800 (Bio-Tek
Instruments, Inc., Winooski, VT, USA) for 30 min every 5 min, at 485 nm to excitation and
530 nm to emission wavelengths [10]. Superoxide dismutase (SOD) activity was assayed
in terms of its ability to inhibit the auto-oxidation of adrenalin to adrenochrome at pH
10.2. Oxidation of adrenalin was measured at 490 nm for 10 min at 30 ◦C as Misra et al.
described [17]. SOD activity was expressed as U/mg prot (1 unit = 50% inhibition of
epinephrine auto-oxidation).
2.6. Glycolysis Capacity
The extracellular acidification rates (ECAR) were measured using the Seahorse Ex-
tracellular Flux XF-24 analyzer (Seahorse Bioscience, N. Billerica, MA, USA). Cells were
plated in XF24 cell culture microplates at a density of 8 × 104 cells/well in DMEM. After
24 h, the culture medium was changed to Base Medium (102353-100, Seahorse Bioscience,
N. Billerica, MA, USA) supplemented with 2 mM glucose and was incubated at 37 ◦C for
1 h in a CO2-free incubator. The extracellular acidification rate (ECAR) was measured using
the XFp Glycolysis Stress Test Kit (Seahorse Bioscience), according to the manufacturer’s
instruction. Accordingly, after baseline measurement, the following injections were made—
10 mM glucose, 1 µM oligomycin, and 50 mM 2-DG. ECAR values were normalized to
the cell number. Cells were counted in a hemocytometer and viability was determined by
trypan blue staining.
2.7. Electron Microscopy Analysis
Electron microscopy analysis was carried out according to the protocol described by
Cebrian et al. [18]. Cells were fixed in 3% glutaraldehyde in PB buffer 0.1 M pH 7.4 and
postfixed in 2% OsO4 and stained in 2% uranyl acetate in the dark. Finally, cells were
dehydrated in ethanol, rinsed with propylene oxide (Lab Baker, Deventry, Holland) and
embedded overnight in Araldite (Durcupan, Sigma). Upon polymerization, embedded
cultures were detached from the chamber slide and glued (Super glue, Loctite) to Araldite
blocks. Semi-thin sections (1.5 µm) were cut with an ultramicrotome (Ultracut UC-6, Leica,
Heidelberg, Germany) mounted onto slides and stained with 1% toluidine blue. Ultrathin
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sections (50 nm) were obtained with an ultramicrotome using a diamond tipped knife
(Ultra 45◦ Diatome) and stained with lead citrate (Reynolds Solution).
Images were obtained with a transmission electron microscope (FEI Tecnai Spirit
BioTwin, Hillsboro, OR, USA) using a digital camera (Morada, Soft Imaging System, Olym-
pus, Tokyo, Japan). At least 10 independent cells were studied for each condition. Among
them, 20 mitochondria were analyzed for each cell culture, belonging up to 2 mitochon-
dria to the same cell. The length of the mitochondrial crests per mitochondrial area was
quantified using the ImageJ software (La Jolla, California, USA).
2.8. Quantification of Mitochondrial Mass
Mitochondrial mass was related to the cardiolipin content. Quantification of cardi-
olipin was performed using the fluorescent probe Nonyl Acridine Orange (NAO, A1372;
Fisher Scientific, Madrid, Spain), according to the protocol described by Shen et al. [10]. The
fluorescence was read using a microplate fluorescence reader FLx800 (Bio-Tek Instruments,
Inc., Winooski, VT, USA), at an excitation wavelength of 485 nm and emission of 530 nm.
2.9. Mitochondrial DNA Copy Number
Human mitochondrial DNA was quantified by real-time PCR in a Stratagene Mx3005P
qPCR System (Agilent Technologies, Inc., Santa Clara, CA, USA), as described by Lopez
LC et al. [19]. We used primers and probe complementary to sequences of the nuclear
gene 18 S (TaqMan Gene Expression Assays Hs99999901_s1, Applied Biosystems) and to
the sequences of the mtDNA 12 S gene. mtDNA values were normalized to nDNA data
(mtDNA/nDNA ratio).
2.10. Cell Proliferation Assay
Cell viability was measured using an MTT assay (MTT, V13154; LifeTechnologies,
Madrid, Spain), based on the conversion of soluble MTT (yellow) to non-soluble formazan
(purple). Cells were seeded in a 96-well culture plate (167008, Thermo Scientific, Madrid,
Spain) and MTT assay was performed following the manufacturer’s instructions.
2.11. Cell Cycle Analysis
Cellular DNA content was measured by flow cytometry using a propidium iodide
(PI)/RNase kit (PI/RNASE, Immunostep, Salamanca, Spain) staining, according to the
manufacturer’s instructions. Data were analyzed using flow cytometry in a Becton Dickin-
son FACSCanto II cytometer (Madrid, Spain). Data were reported as the percentage of cells
in each phase of the cell cycle.
2.12. Western Blot Analysis
Protein extraction and Western blot analyses were performed as described previ-
ously [20], and Bradford assay was used to determine protein concentration. Adequate
amounts of proteins were separated on 7% and 12.5% PhastGel homogeneous gels (GE
Healthcare Life Sciences, Barcelona, Spain). Proteins were transferred to Hybond™-ECL
nitrocellulose membranes (GE Healthcare Life Sciences, Barcelona, Spain) using the Phast-
System (GE Healthcare Life Sciences, Barcelona, Spain). Next, the membranes were first
incubated in blocking buffer containing 5% BSA in PBS plus 0.1% Tween 20 and were
then, incubated with the primary antibodies diluted in blocking buffer overnight at 4 ◦C.
The utilized primary antibodies included OXPHOS Rodent WB Antibody Cocktail (1:1000;
ab110413; Abcam, Inc., Cambridge, MA,USA), OPA1 (1:200; sc393296; Santa Cruz Biotech-
nology, Heidelberg, Germany), MFN2 (1:200; sc5033; Santa Cruz Biotechnology), Drp1
(1:200; sc-32898; Santa Cruz Biotechnology), LETM (1:200; sc-134672; Santa Cruz Biotechnol-
ogy), Bax (1:200; sc-526; Santa Cruz Biotechnology), Bcl2 (1:200; sc-492; Santa Cruz Biotech-
nology), NIX (1:1000; N0399; Sigma-Aldrich, Madrid, Spain), LC3 (1:1000; nb100-2220;
Novus, Abigdon, UK), ATG12 (1:200; sc-271688; Santa Cruz Biotechnology), MT1 (1:500;
TA321736; OriGene Technologies, Rockville, MD, USA), MT2 (1:500; TA314217; OriGene
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Technologies), RORα (1:500; TA311450; OriGene Technologies), and GAPDH (1:500; sc-
166574; Santa Cruz Biotechnology). Anti-mouse at dilution 1:1000 (554002; BD Biosciences
Pharmigen, San Jose, CA, USA), anti-rabbit at dilution 1:5000 (31460; Thermo Scientific,
Madrid, Spain), and anti-goat diluted 1:1000 (sc-2768; Santa Cruz Biotechnology) HRP
conjugated secondary antibodies were used according to the manufacturer’s instructions.
The images were analyzed using the ECLTM Prime Western Blotting Detection
Reagent (GE Healthcare Life Sciences, Barcelona, Spain), with the Kodak Image Station
2000R (Eastman Kodak Company, Rochester, NY, USA), and quantified using 1D Image
Analysis software 3.6. Protein band intensities were normalized to GAPDH and data were
expressed as the percentage relative to controls.
2.13. Statistical Analysis
Data are expressed as the mean ± S.E.M of a minimum of three independent experi-
ments. Statistical analysis was performed with the Prism software (GraphPad, La Jolla, CA,
USA), using one-way analysis of variance (ANOVA) with Bonferroni test. Normality test
was performed by a Shapiro-Wilk analysis, showing that all date had a normal distribution.
A p-value of < 0.05 was considered to indicate statistical significance.
3. Results
3.1. Melatonin Up-Regulates Key TCA Cycle Metabolites in HNSCC Cells
The role of melatonin in regulating cancer cell metabolism remains largely unex-
plored. To further dissect the effects of melatonin in cancer metabolism, we carried out
metabolomic analyses using UPLC-MS/MS, which found clear differences between the
control group and the melatonin-treated cells (Figure 1). We found that after 6 h, melatonin-
treated cells upregulated key TCA cycle metabolites, including acetyl CoA, citric acid, and
succinyl-CoA (Figure 1A–C), which led to increased NADH levels (Figure 1D) and reduced
levels of pyruvate (Figure 1E). A larger influx of pyruvate into the mitochondria plus the
increased NADH levels would lead to enhanced oxidative phosphorylation. These two
processes would lead to mitochondrial ROS production. Interestingly, the intracellular
lactate increased, compared to the control (Figure 1F).
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Antioxidants 2021, 10, 603 7 of 20
These findings corroborated the important role played by melatonin to induce a
change of head and neck cancer cell metabolism. To independently validate these data, we
then assessed the mitochondrial respiration and glycolytic capacity.
3.2. Melatonin Treatment Induces Uncoupling between Respiration and Phosphorylation in
Mitochondria, Correlating with Increased ROS Production in HNSCC Cells
To further determine whether the inhibition of metabolic reprogramming in HNSCC
cells after melatonin treatment was linked to their mitochondria activity, functional mito-
chondrial analyses were carried out using the Seahorse XF24 extracellular flux analyzer
in Cal-27 cells (Figure 2A–C) and in SCC-9 cells (Figure 2D–F). Consistent with previous
findings [10,11], we observed elevated OCR corresponding to increased basal respiration
(Figure 2G–I) and maximal respiratory capacity of the electron transport system (ETS),
with melatonin treatment of Cal-27 cells in a dose- and time-dependent direct manner
(Figure 2J–L). However, at high 500 and 1500 µM doses of melatonin during 3 and 5 days
of treatment, melatonin reduced the OCR (Figure 2H,I,K,L), suggesting that the mito-
chondrial function was defective during long treatments with higher concentrations of
melatonin. SCC-9 cells showed no significant differences in basal respiration and ETS
capacity (Figure 2G,H), but exhibited a significant decrease in mitochondrial respiration,
after 3 and 5 days of melatonin treatment at a dose of 1500 µM (Figure 2H,I,K,L). Thus,
confirming the presence of defective mitochondria at high doses of melatonin. No signifi-
cant changes in ATP turnover were observed in either group tested, following melatonin
treatment (Figure 2M–O).
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We then examined OXPHOS protein expression levels by Western blotting (Figure 3).
In Cal-27 cells, protein analysis showed that treatment with melatonin led to a significant
increase in the expression of complexes I, II, III, and IV, relative to the control cells, espe-
cially after 1 and 3 days of treatment (Figure 3A–D). The rate of increase in their expression
levels fell after 5 days of treatment (Figure 3E,F), which was consistent with the results for
mitochondrial respiratory function. However, no differences in the expression levels of
complex V or ATP synthase were observed in any melatonin-treated groups (Figure 3). This
correlated with mitochondrial ATP turnover, which remained unchanged (Figure 2M–O).
Although SCC-9 cells were more resistant than Cal-27 cells, its values indicated a par-
tial uncoupling between respiration and phosphorylation in mitochondria, which could
correlate with an increase in ROS production. Thus, we found that melatonin treatment
was able to induce significant levels of ROS production in Cal-27 cells, in a dose- and
time-dependent manner (Figure 4A,B). However, ROS production decreased after 5 days
of melatonin treatment (Figure 4C), which correlated with the decrease in mitochondrial
function. The increase in ROS levels was an indication of the weak scavenging ability of
cancer cells. We therefore measured superoxide dismutase (SOD) activity (Figure 4D–F),
which constituted the first line of defense against excess ROS. SOD activity was found to
significantly decrease following treatment with melatonin, in a dose- and time-dependent
manner, thus, confirming that melatonin increased oxidative stress in cancer cells.
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3.3. Effects of Melatonin on Glycolytic Activity in HNSCC Cells
Cancer cells are able to use different energy sources. In order to clarify the metabolic
flux of HNSCC treated with melatonin, we focused on glycolytic activity, due to its prime
role in cancer cell proliferation. Our investigation of the effects of melatonin on glycolytic
activity in HNSCC cells showed a decrease in the extracellular acidification rate (ECAR),
after 3 and 5 days of tre ment with high doses f melatonin (Figure 5A–F). Cellular
glycolytic reserve capacity, calculated by subtracting the maximal ECAR from the basal rate,
increased significantly, following melatonin treatment, reaching a peak at a dose of 500 µM,
after 1 and 3 days of treatment, as compared to the basal control group (Figure 5G–I).
With regard to the effect of melatonin treatment on HNSCC glycolysis, hexokinase II
(HK-II) protein levels were determined. Treatment with 500 µM of melatonin significantly
decreased the hexokinase II (HK-II) protein content in Cal-27 cancer cells, after 5 days of
treatment (Figure 5J–L).
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3.4. Melatonin Treatment Modifies the Mitochondrial Morphology of HNSCC Cells
To determine whether the changes in mitochondrial function observed in HNSCC
cells correlated with compromised mitochondrial structural integrity, we evaluated mito-
chondrial morphology by electron microscopy (EM). As shown in Figure 6A, mitochondria
size was larger in Cal-27 cells treated with melatonin, as compared to the control group.
Similar results were observed for the SCC-9 cells (images not shown). Mitochondria in
the control group showed a more spheroid and ovoid morphology with poor cristae, as
compared to the elongated mitochondria with well-defined cristae in melatonin-treated
cells, especially at higher melatonin concentrations of 500 and 1500 µM, indicative of a
high metabolic rate. Interestingly, the effects of melatonin on Cal-27 cells, which became ev-
ident after one day of treatment, were maintained throughout the treatment (Figure 6A–D).
However, melatonin had a more marked impact on SCC-9 cells than on Cal-27 cells, only
after three days of treatment, with no effect being observed after five days (Figure 6C,D).
These results were consistent with the increase in mitochondrial mass, as compared to the
control group, especially at a concentration of 1500 µM, after one day of treatment in Cal-27
cells (Figure S1A) and at concentrations of 500 and 1500 µM after three days of treatment
in both cell lines (Figure S1B). We again observed that long-term treatment with high doses
of melatonin damaged mitochondria (Figure S1C).
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Figure 6. Melatonin-induced changes in mitochondrial morphology. Alterations in mitochondrial morphology analyzed
by EM in Cal-27 cells (A), cristae length analyzed using the Image J software (B–D) in Cal-27 (in blue) and SCC-9 cells
(in black and grey). In the control cells, the typical morphology of the Cal-27 mitochondria could be observed, with a
round shape and few mitochondrial cristae (asterisks). No changes were detected over time. With aMT 100 concentration,
mitochondria tend to get smaller and adopt elongated shapes, especially after 5 days of treatment (arrows). At dose of aMT
500, mitochondria do not show much change between day 1 and day 3, but at 5 days, mitochondria can be seen with a
marked increase in cristae number (asterisks). At a concentration of 1500, at one day of treatment, mitochondria are similar
to those in the control cells, although heterogeneous dense bodies are occasionally appreciated (arrows). After 3 days
of treatment, the mitochondria maintain their shape and appearance, with abundant cristae. After 5 days, dense bodies
continue to be seen (arrows) and it is difficult to detect cristae in some mitochondria. n = 6 per group. Data are presented as
mean ± SEM. ** p < 0.01, *** p < 0.001 vs. control; ### p < 0.001 vs. aMT 100 µM group; $$$ p < 0.001 vs. aMT 500 µM group.
Scale bar = 1 µm.
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In addition, it was reported that during reprogramming there was not only a reduction
of mitochondrial mass, but also in mitochondrial DNA (mtDNA) [21]. Consistent with
the comparable increase in mitochondrial mass, we observed a sharp increase in mtDNA
(Figure S1D,F), especially after one day of treatment with 1500 µM of melatonin in Cal-27
cells (Figure S1D). However, three days of treatment with high concentrations of melatonin
led to a progressive increase in the mtDNA copy number, while the results for mtDNA in
SCC-9 cells were in line with those for the mitochondrial mass (Figure S1E,F).
3.5. Melatonin Alters Mitochondrial Fission and Fusion in HNSCC Cells
To explore the mechanism underlying melatonin-induced mitochondrial elongation in
tumor cells, we analyzed the expression levels of the core components in mitochondrial fis-
sion/fusion machinery by Western blot. We measured the inner mitochondrial membrane
protein, optic atrophy1 (OPA1), and outer mitochondrial membrane protein, mitofusin
2 (MFN2), which control mitochondrial fusion, the dynamin-related protein 1 (Drp1), is
mainly involved in mitochondrial fission [22], and the leucine zipper/EF hand-containing
transmembrane-1 (LETM1), which acts as an anchor protein for complex formation between
mitochondria and ribosome, and as a regulator of mitochondrial biogenesis (Figure 7) [23].
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Melatonin decreased OPA1 and MFN2 l vels in Cal-27 c lls af er three and five days of
treatment, as compared to the control gr up (Figure 7A–F,M), with a peak effect observed
at a concentration of 500 µM. In addition, Drp1 protein levels increased at concentrations
of 500 and 1500 µM after one day of treatment, and decreased after 5 days of treatment
(Figure 7G–I,M). Similar results were observed with regard to LETM1 (Figure 7J–M) [24].
Overall, these findings indicate that melatonin increases mitochondrial fission after
24 h, which then decreases after 5 days of treatment. While melatonin decreased fusion, the
downregulation of mitochondrial fission was reported to increase cancer cell apoptosis [25].
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On the other hand, the percentage of apoptotic cells increased as OPA1 and MFN2 gene
expression levels fall [26].
3.6. Melatonin Increases Apoptosis and Autophagy in HNSCC Cells
We evaluated the expression levels of apoptotic proteins by Western blot. Mela-
tonin increased Bax (Figure 8A–C,J) and decreased Bcl-2 (Figure 8D–F,J) expression levels,
with an increase also observed in the Bax/Bcl-2 ratio (Figure 8G–I), following dose- and
time-dependent melatonin treatment, reaching a peak effect after three and five days at
concentrations of 1500 or 500 µM, respectively, in Cal-27 cells.
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Figure 8. Increases in apoptosis and autophagy caused by melatonin in Cal-27 cells. Western blot analysis of Bax (A–C,J),
Bcl-2 (D–F,J), Bax/Bcl-2 ratio (G–I), NIX (K–M,T), LC3 (N–P,T), and ATG12-ATG5 (Q–T). Data for aMT 1500 group are
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aMT 500 µM group.
In addition, oxidative stress is well-known to promote autophagy, which boosts the mi-
tophagic removal of damaged mitochondria [27]. We then analyzed autophagy/mitophagy
activation and determined ATG12-ATG5, LC3-II, and NIX protein levels (Figure 8K–T).
Interestingly, ATG12-ATG5 protein levels gradually decreased after three days of
melatonin treatment, at concentrations of 500 and 1500 µM (Figure 8R,T). In contrast, LC3-
II protein levels increased during all dose-dependent melatonin treatments (Figure 8N–P,T),
which also induced an accumulation of NIX proteins (Figure 8K–M,T).
Thus, melatonin increased NIX- and LC3-dependent mitophagy, while ATG-dependent
autophagy remained unchanged.
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3.7. Melatonin Decreases HNSCC Cell Proliferation and Induces Cell Cycle Arrest in the G1 and
G2/M Phases
As mitochondria are essential for cancer cell proliferation, with several cell signaling
mitochondria known to be involved in controlling cell cycle progression [28], we mea-
sured cell proliferation by the MTT assay. We observed morphological changes such as
cell detachment and shrinkage, especially at high concentrations of melatonin (500 and
1500 µM) after 3 and 5 days of treatment (Figure 9A); cellular proliferation was suppressed
by dose- and time-dependent treatment with melatonin as compared to the control group
(Figure 9B–D), with maximal effect achieved at a concentration of 1500 µM, although SCC-9
cells were found to be more resistant to treatment than Cal-27 cells.
Figure 9. Decreased proliferation of Cal-27 and SCC-9 cells caused by melatonin. Morphological alterations (A), proliferation
rate (B–D), percentage of cells in each cell cycle phase (E–G), and representative plots showing cell redistribution (H). Data
for aMT 1500 group are not shown at day 5 because most cells died. n = 6 per group. Data are presented as mean ± SEM.
* p < 0.05, ** p < 0.01, *** p < 0.001 vs. control; ## p < 0.01, ### p < 0.001 vs. aMT 100 µM group; $ p < 0.05, $$ p < 0.01,
$$$ p < 0.001 vs. aMT 500 µM group.
To determine whether the inhibition of proliferation induced by melatonin is involved
in the cell cycle arrest, we evaluated its impact on the Cal-27 cell cycle by flow cytometry.
As shown in Figure 9E–H, concentration- and time-dependent treatment with melatonin
significantly increased the percentage of cells in the G1 and G2/M phases and decreased
Cal-27 cell proliferation in phase S of the cell cycle.
These results showed that melatonin had selective anti-proliferative effects on HN-
SCC cells.
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3.8. High Doses of Melatonin Change Melatonin Receptor Protein Levels
Given that the functions of melatonin are mediated by both receptor-dependent
and receptor-independent mechanisms [29], we then explored the involvement of mela-
tonin receptors in the cytotoxic effects of melatonin on HNSCC by Western blot analysis
(Figure S2).
Incubation of cells with melatonin significantly increased MT1 gene expression after
one and three days of dose-dependent treatment (Figure S2A,B,J). However, MT1 expres-
sion decreased after five days of treatment with 500 µM of melatonin (Figure S2C,J). These
data are consistent with the cellular damage produced by long treatments with high doses
of melatonin.
On the other hand, dose- and time-dependent melatonin treatment led to a marked
decrease in MT2 and RORα levels (Figure S2D–J).
4. Discussion
Metabolic reprogramming by cancer cells to rapidly adapt to stress conditions such as
hypoxia and limited nutrients is now avowed as hallmarks of cancer, with several recent
studies shedding light on the role of mitochondria in this process [5,30]. The integration of
tumor cell metabolism reprogramming into novel cancer therapies attracts considerable
interest in the cancer research community [31–35], with mitochondrial metabolism, in
particular, being an important potential target for therapeutic intervention [5,36].
On the whole, cancer cells use glycolysis rather than mitochondrial respiration, even
in presence of sufficient oxygen, to produce ATP molecules [37]. Our findings indicate that
glycolysis inhibition and increased OXPHOS activity could explain, at least partially, the
inhibition of metabolic reprogramming by melatonin in HNSCC cells. OXPHOS deficiency
also closely correlates with the invasive and metastatic properties of tumor cells [38]. Our
results conclude that melatonin treatment increases TCA intermediates such as acetyl-CoA,
citric acid, and succinyl-CoA, as well as NADH, but decreases pyruvate levels. The influx
of pyruvate into mitochondria, which connects glycolysis, with no oxygen requirement, to
mitochondrial oxidative phosphorylation, is a critical metabolic process. Pyruvate directly
drives the metabolic flux of the TCA cycle forward, through conversion to acetyl-CoA by
pyruvate dehydrogenase, with the condensation of acetyl-CoA with oxaloacetate leading to
the formation of citrate. In addition to increasing acetyl-CoA and citrate levels, melatonin
could counteract reductions in mitochondrial pyruvate carrier (MPC) tumor cell activity
and in pyruvate oxidation rates [39]. Pyruvate is also shunted away from the cancer
cell mitochondrial metabolism through its reduction to lactate. Lactate dehydrogenase
A (LDHA) reduces pyruvate to lactate and, at the same time, oxidizes NADH to NAD+,
thus explaining the low levels of cancer cell NADH. Melatonin increased both NADH
and intracellular lactate levels, suggesting that extracellular lactate transport is inhibited.
The transport of lactate out of the cell acidifies the tumor microenvironment, allowing
progression to metastasis due to suppression of local immune response and activation of
metalloproteases [8,40]. Melatonin was found to increase intracellular lactate, suggesting
that lactate transport is inhibited following melatonin treatment.
We decided to determine the impact of melatonin on the behavior of mitochondria in
cellular metabolism. Our results showed that melatonin stimulates oxygen consumption,
basal respiration, and ETS capacity, and increases OXPHOS protein expression levels.
Surprisingly, mitochondrial intracellular ATP turnover did not increase in either Cal-27
or SCC9 cell lines following melatonin treatment. Complex V (ATP synthase) protein
expression was unaffected despite an overall increase in OXPHOS markers, such as com-
plex I-IV and respiratory function. These results could be attributed to the uncoupling of
mitochondrial electron transport activity and phosphorylation. Both cellular respiration
and ATP production were selectively affected in tumor cells, indicating that the mito-
chondrial bioenergetic inhibition was a selective mechanism caused by melatonin. In
addition, incomplete oxidative phosphorylation in the electronic transport chain results in
an increase in ROS. Melatonin was observed to increase ROS production in a dose- and
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time-dependent manner, which was partly due to decreased mitochondrial SOD activity.
High levels of mitochondrial SOD are well-known to greatly stimulate glycolysis through
H2O2 production and activation of specific signaling pathways and to strongly inhibit
mitochondrial oxidative metabolism [41]. However, the complex role of ROS in mediating
tumor progression remains a subject of controversy. Several studies concluded that ROS, as
signaling molecules, facilitate cancer stem cell (CSC) self-renewal and expansion [42], stim-
ulated cell invasiveness [43], and potentiated tumor progression. Nonetheless, increased
ROS levels were also reported to be detrimental to other cancer cells and to inhibit cancer
metastasis [42]. Furthermore, restoration of OXPHOS activity and increased levels of ROS
can sensitize CSCs to chemotherapeutic drugs [44].
Glycolysis is generally used by cancer cells for ATP production rather than mitochon-
drial respiration, even in the presence of adequate oxygen [37]. In addition, resistant cells
can acquire a glycolytic metabolism to survive cytotoxic stress [38]. Given that glycolytic
marker expression in HNSCC is associated with poor survival rates and resistance to chemo
and radiotherapy [2], we observed that melatonin decreases glycolysis. On the whole,
these findings indicate that glycolysis inhibition and increased OXPHOS might explain, at
least partly, the inhibition of metabolic reprogramming induced by melatonin in HNSCC
cells [38].
Mitochondrial metabolic reprogramming is shown to be necessary for tumorigenesis,
metastasis, and stemness [5,30]. Guido et al. suggested that remodeling of mitochondrial
morphology protects tumor cells against cellular stress with remarkable success, and
therefore, that adjustment of mitochondrial morphology could be a potential tool in human
cancer treatment [45]. It was suggested that mitochondrial dynamic changes act as sensors
of energy stress and initiators of cancer cell metabolic reprogramming [46]. However, the
effects of melatonin on reprogrammed metabolism mediated by the changes in cancer
cell mitochondrial morphology are little understood. Our study showed that melatonin
induced mitochondrial elongation and facilitated the formation of cristae in HNSCC cells
and thus increased mitochondrial mass. The shape of cristae was also demonstrated to
regulate the stability and assembly of respiratory chain supercomplexes, which affected
respiratory efficiency [27]. It was possible to speculate that mitochondrial elongation
correlated with a clear metabolic shift from glycolysis to oxidative phosphorylation.
Mitochondrial functions were closely associated with the morphodynamics of mito-
chondria, consisting of both fusion and fission processes. In general, fission, whose pro- or
anti-apoptotic function remains a matter of debate, is thought to be pro-tumorigenic [25].
On the other hand, some authors showed that an increase in activation of mitochondrial
fusion in cancer is a metabolic advantage to maintain tumor growth [26]. In this study
we found that melatonin decreased fusion and fission after 5 days of treatment. Our
results appear to be congruent with the finding that mitochondrial fusion proteins are
responsible for maintaining mitochondrial membrane structures, matrix homogeneity,
and mitochondrial genome integrity, which are vital for cell survival [47]. In addition,
the loss of fusion/fission balance is linked to mitochondrial and cellular dysfunctions
such as apoptosis. Other studies demonstrated that certain anti-tumor drugs activate
autophagy while inducing apoptosis [10,48]. This is in line with our finding that melatonin
triggers apoptosis in a dose- and time-dependent manner. Melatonin leads to a decrease
in anti-apoptotic factors and to a release of pro-apoptotic factors from the mitochondrial
inter-membrane space into the cytosol. This could be partly due to severe impairment of
the mitochondrial electron transport chain, which is a major site of ROS production [49].
ROS production triggers mitochondrial autophagy and protein degradation in order to
mitigate the cellular stress induced by melatonin. However, autophagy, which plays a dual
role, can induce senescence or cell death as a tumor suppressor and can also induce tumori-
genesis [50]. Reprogrammed cancer cells, undergoing glycolysis, display mitochondrial
dysfunction and activate autophagy/mitophagy [51]. Although the specific mechanism of
autophagy involved in cancer cells remains largely unknown, Atg5-dependent autophagy
was shown to be transiently activated early on the reprogramming process [52], which
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was blocked in Agt5−/− cells in particular. This was consistent with our results which
showed that melatonin decreased glycolysis and ATG5 levels after three days of treatment,
although melatonin was also found to induce mitophagy and apoptosis.
We found that the cytotoxic effects of melatonin in decreasing cell proliferation are
dose- and time-dependent. We show that high doses of melatonin, such as those used in
this study and elsewhere [20], with their cytotoxic effect on HNSCC cells, further increased
melatonin receptor expression, which might be involved, at least partly, in the indoleamine
effect [12].
5. Conclusions
In conclusion, we showed that melatonin increased mitochondrial TCA intermediates
and OXPHOS levels, resulting in an inhibition of metabolic reprogramming of aerobic
glycolysis. Overall, the study provides new insights into the mechanisms underlying
melatonin’s anti-tumor activity in head and neck cancer cells. To the best of our knowledge,
this was the first study to demonstrate that the anti-proliferative effects of melatonin in
HNSCC are, at least partially, due to an inhibition of metabolic remodeling, resulting in
enhanced mitochondrial function. This, in turn, leads to increased oxidative stress and
activation of apoptosis and mitophagy in HNSCC cells.
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